ERBB2 and breast carcinoma: Collectively, our studies demonstrated that dysregulation of PPP3CB-FOXO3a axis resulted in increased expression of both IGF2 and IRS1, which in turn disrupted the negative feedback inhibition loop of IGF-1R-initiated signaling, subsequently conferring Herceptin resistance in HER2-positive breast cancer.